

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Wed, 25 Mar 2020 15:01:21 +0000  
**To:** DELFRAISSY Jean-francois  
**Cc:** (b) (6)  
**Subject:** RE: France situation COVID-19

Jean-Francois:

Thank you for your note. I do not see Yazdan copied on your e-mail, and so please forward this e-mail to him. The NIH position is that we should preferably make drugs available on randomized, controlled clinical trials and not freely distribute them. There is a strong push in the USA, favored by the President, to make certain of these drugs more widely available outside of an RCT using mechanisms such as "compassionate usage". In the USA, as you know, HC (plaquenil) is an approved drug for malaria as well as for certain autoimmune diseases such as SLE. Thus, physicians can prescribe the drug on an "off label" usage. This likely will be the major modality of distribution of this drug in the USA, at least for the foreseeable future.

I am copying Cliff Lane on this e-mail. Please include him on any further correspondence on this subject.

Best regards,

Tony

Anthony S. Fauci, MD  
Director  
National Institute of Allergy and Infectious Diseases  
Building 31, Room 7A-03  
31 Center Drive, MSC 2520  
National Institutes of Health  
Bethesda, MD 20892-2520  
Phone: (b) (6)  
FAX: (301) 496-4409  
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

---

**From:** DELFRAISSY Jean-francois (b) (6)>  
**Sent:** Wednesday, March 25, 2020 10:35 AM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b) (6)>  
**Cc:** DELFRAISSY Jean-francois (b) (6)>  
**Subject:** France situation COVID-19